The European Commission and the EMA published a Public Call for Expression of Interest as representative of Patients' Associates and Clinicians to the Commitee for Advanced Therapy Medicinal Products (CAT) of the European Medicines Agency.
Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products1 ("the Regulation") lays down specific rules concerning the authorisation, supervision and pharmacovigilance of advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue engineering). Central to the operation of this Regulation is the Committee for Advanced Therapies (CAT) established as part of the EMA.
The members of the CAT are appointed for a renewable period of three years. The three year term of the current members started on January 2009 and this call is intended to select candidates to replace them. Current members may reapply.
The CAT is composed of:
Get more details about the CAT on the EMA website - CAT: Overview.